BeOne Medicines (ONC) said Thursday that the phase 1 study of sonrotoclax plus BRUKINSA elicited a 96% overall response rate in relapsed/refractory chronic lymphocytic leukemia patients and a 79% overall response rate in relapsed/refractory mantle cell lymphoma patients.
BGB-16673 also showed "strong early results" in hard-to-treat populations, and the data support future regulatory filings and the progression of sonrotoclax and BGB-16673 into phase 3 studies, the company said.
The company's shares were up nearly 5% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.